Atossa Therapeutics
ATOS
53 hedge funds and large institutions have $22.8M invested in Atossa Therapeutics in 2021 Q1 according to their latest regulatory filings, with 37 funds opening new positions, 11 increasing their positions, 3 reducing their positions, and 3 closing their positions.
1,416% more capital invested
Capital invested by funds: $1.51M → $22.8M (+$21.3M)
1,133% more first-time investments, than exits
New positions opened: 37 | Existing positions closed: 3
267% more repeat investments, than reductions
Existing positions increased: 11 | Existing positions reduced: 3
179% more funds holding
Funds holding: 19 → 53 (+34)
124% more call options, than puts
Call options by funds: $10.2M | Put options by funds: $4.57M
0.77% more ownership
Funds ownership: 0.24% → 1.01% (+0.77%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$6.85M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$6.49M |
| 3 |
BlackRock
New York
|
+$3.73M |
| 4 |
CH
CVI Holdings
Wilmington,
Delaware
|
+$1.05M |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$970K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$142K |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$23.6K |
| 3 |
VF
Virtu Financial
New York
|
-$8.22K |
| 4 |
Simplex Trading
Chicago,
Illinois
|
-$987 |
| 5 |
Group One Trading
Chicago,
Illinois
|
-$256 |
ATOS Hedge Fund Activity: Q1 2021 in Review
53 of the 5,711 institutional investors tracked by Wall St. Rank reported a position in Atossa Therapeutics (ATOS) for Q1 2021, worth a combined $22.8M — up 1,416% from $1.51M a quarter earlier.
Buyers outnumbered sellers: 37 funds opened new ATOS positions and 3 closed out — a net gain of 34 holders — while 11 added to existing stakes and 3 trimmed.
The largest buyer was Renaissance Technologies, adding an estimated $6.85M. The largest seller was Susquehanna International Group, cutting an estimated $142K.
- 53 institutional investors held Atossa Therapeutics (ATOS) as of Q1 2021, up from 19 in Q4 2020.
- Funds reported $22.8M of Atossa Therapeutics stock for Q1 2021, up 1,416% quarter-over-quarter.
- 37 funds opened new Atossa Therapeutics positions in Q1 2021 and 3 closed out, a net change of +34 holders.
- The largest Atossa Therapeutics buyer in Q1 2021 was Renaissance Technologies, an estimated $6.85M added.
- The largest Atossa Therapeutics seller in Q1 2021 was Susquehanna International Group, an estimated $142K sold.
Based on aggregated 13F filings for Q1 2021.